Comparison between Senores Pharmaceuticals IPO and Standard Glass Lining IPO.
Senores Pharmaceuticals IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Standard Glass Lining IPO is a Mainboard Bookbuilding proposed to list at NSE, BSE.
The total issue size of Senores Pharmaceuticals IPO is up to ₹582.11 Cr whereas the issue size of the Standard Glass Lining IPO is up to ₹410.05 Cr. The final issue price of Senores Pharmaceuticals IPO is ₹391.00 per share and of Standard Glass Lining IPO is ₹140.00 per share.
| Senores Pharmaceuticals IPO | Standard Glass Lining IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹372.00 per share | ₹133.00 per share |
| Issue Price (Upper) | ₹391.00 per share | ₹140.00 per share |
| Issue Price (Final) | ₹391.00 per share | ₹140.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 38 shares | 107 shares |
| Fresh Issue Size | 1,27,87,723 shares | 1,50,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹500.00 Cr | up to ₹210.00 Cr |
| OFS Issue Size | 21,00,000 shares | 1,42,89,367 shares |
| OFS Issue Size (Amount) | up to ₹82.11 Cr | up to ₹200.05 Cr |
| Issue Size Total | 1,48,87,723 shares | 2,92,89,367 shares |
| Issue Size Total (Amount) | up to ₹582.11 Cr | up to ₹410.05 Cr |
Senores Pharmaceuticals IPO opens on Dec 20, 2024, while Standard Glass Lining IPO opens on Jan 06, 2025. The closing date of Senores Pharmaceuticals IPO and Standard Glass Lining IPO is Dec 24, 2024, and Jan 08, 2025, respectively.
| Senores Pharmaceuticals IPO | Standard Glass Lining IPO | |
|---|---|---|
| Anchor Bid Date | Dec 19, 2024 | Jan 03, 2025 |
| Issue Open | Dec 20, 2024 | Jan 06, 2025 |
| Issue Close | Dec 24, 2024 | Jan 08, 2025 |
| Basis Of Allotment (Tentative) | Dec 26, 2024 | Jan 09, 2025 |
| Initiation of Refunds (Tentative) | Dec 27, 2024 | Jan 10, 2025 |
| Credit of Share (Tentative) | Dec 27, 2024 | Jan 10, 2025 |
| Listing date (Tentative) | Dec 30, 2024 | Jan 13, 2025 |
| Anchor Lockin End date 1 | Jan 24, 2025 | Feb 07, 2025 |
| Anchor Lockin End date 2 | Mar 25, 2025 | Apr 08, 2025 |
Senores Pharmaceuticals IPO P/E ratio is 39.77, as compared to Standard Glass Lining IPO P/E ratio of 43.04.
| Senores Pharmaceuticals IPO | Standard Glass Lining IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 66.67 | 72.49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 45.77 | 67.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 39.77 | 43.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹1350.70 Cr. | ₹2792.88 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 23.60% | 20.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 11.73% | 25.49% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.07 | 0.32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹9.83 | ₹3.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 23.60% | 20.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Senores Pharmaceuticals IPO Retail Individual Investors (RII) are offered 14,81,272 shares while in Standard Glass Lining IPO retail investors are offered 14,81,272 shares. Qualified Institutional Buyers (QIB) are offered 44,43,818 shares in Senores Pharmaceuticals IPO and 58,57,875 shares in Standard Glass Lining IPO.
| Senores Pharmaceuticals IPO | Standard Glass Lining IPO | |
|---|---|---|
| Anchor Investor Reservation | 66,65,725 shares | 87,86,009 shares |
| Market Maker Reservation | ||
| QIB | 44,43,818 shares | 58,57,875 shares |
| NII | 22,21,908 shares | 43,93,406 shares |
| RII | 14,81,272 shares | 1,02,51,279 shares |
| Employee | 75,000 shares | |
| Others | ||
| Total | 1,48,87,723 shares | 2,92,88,569 shares |
Senores Pharmaceuticals IPO subscribed 97.86x in total, whereas Standard Glass Lining IPO subscribed 185.48x.
| Senores Pharmaceuticals IPO | Standard Glass Lining IPO | |
|---|---|---|
| QIB (times) | 97.84x | 327.76x |
| NII (times) | 100.35x | 275.21x |
| Big NII (times) | 95.25x | 302.21x |
| Small NII (times) | 111.35x | 221.21x |
| RII (times) | 93.16x | 65.71x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 97.86x | 185.48x |
